Health Technology
Eisai Co., Ltd.
In the news
- Japan and Western drugmakers launch $1bn fund against superbugs Jul 10, 2020
- Japan's Eisai to launch clinical trial for coronavirus treatment Jul 1, 2020
- Corporate inertia stops Japan from moving annual meetings online Jun 13, 2020
- With profits rolling in, corporate Japan trims its workforce Feb 9, 2020
- Governance demands chip away at Japanese cross-shareholdings Jul 8, 2019 See more articles on Eisai Co., Ltd.
Business Summary
Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.
Financial Highlights
| Mar 2020 | JPY | USD |
| Revenue | 695,621M | 6,397.94M |
| Gross Profit | 510,352M | 4,693.93M |
| Operating income | 138,679M | 1,275.49M |
| Income before tax | 128,063M | 1,177.85M |
| Net income | 121,767M | 1,119.94M |
| EBITDA | 172,379M | 1,585.44M |
| Diluted EPS | 424.79 | 3.90 |
| Dividends Per Share | 160 | 1.47 |
| Total Assets | 1,062.14B | 9,838.72M |
| Total liabilities | 359,509M | 3,330.17M |
| Total equity | 678,127M | 6,281.57M |
| Operating cash flow | 102,782M | 945.33M |
| Currency in JPY | Currency in USD |
Historical Data
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
| Revenue | 547,922M | 539,097M | 600,054M | 642,834M | 695,621M |
| Gross Profit | 339,839M | 331,091M | 386,599M | 446,436M | 510,352M |
| Operating income | 42,779M | 51,205M | 75,595M | 99,921M | 138,679M |
| Income before tax | 50,473M | 57,668M | 76,803M | 89,454M | 128,063M |
| Net income | 54,933M | 39,359M | 51,845M | 63,386M | 121,767M |
| EBITDA | 76,843M | 77,689M | 101,778M | 126,762M | 172,379M |
| Diluted EPS | 191.76 | 137.41 | 180.97 | 221.11 | 424.79 |
| Dividends Per Share | 150 | 150 | 150 | 150 | 160 |
| Total Assets | 973,987M | 1,030.76B | 1,049.03B | 1,071.52B | 1,062.14B |
| Total liabilities | 397,159M | 428,172M | 434,934M | 419,539M | 359,509M |
| Total equity | 573,660M | 584,630M | 593,582M | 628,120M | 678,127M |
| Operating cash flow | 95,617M | 75,851M | 149,649M | 103,714M | 102,782M |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
| Revenue | 4,562.81M | 4,978.38M | 5,414.06M | 5,796.79M | 6,397.94M |
| Gross Profit | 2,830.00M | 3,057.51M | 3,488.14M | 4,025.76M | 4,693.93M |
| Operating income | 356.24M | 472.86M | 682.06M | 901.04M | 1,275.49M |
| Income before tax | 420.31M | 532.54M | 692.96M | 806.65M | 1,177.85M |
| Net income | 457.45M | 363.46M | 467.77M | 571.58M | 1,119.94M |
| EBITDA | 639.90M | 717.43M | 918.30M | 1,143.08M | 1,585.44M |
| Diluted EPS | 1.59 | 1.26 | 1.63 | 1.99 | 3.90 |
| Dividends Per Share | 1.24 | 1.38 | 1.35 | 1.35 | 1.47 |
| Total Assets | 8,665.75M | 9,250.32M | 9,863.94M | 9,680.80M | 9,838.72M |
| Total liabilities | 3,533.60M | 3,842.51M | 4,089.64M | 3,790.38M | 3,330.17M |
| Total equity | 5,103.96M | 5,246.61M | 5,581.39M | 5,674.84M | 6,281.57M |
| Operating cash flow | 796.24M | 700.45M | 1,350.22M | 935.24M | 945.33M |
Valuation Measures
| Mar 2020 | |
| PER | 18.66 |
| ROA | 11.41% |
| ROE | 18.64% |
| Operating margin | 19.93% |
| Profit margin | 17.50% |
Key executives
- Chief Executive Officer & Representative Director: Haruo Naito
- COO, Representative Executive Officer & Head-China: Yasushi Okada
- Chief Financial Officer: Ryohei Yanagi
- Chief Medical Officer & Managing Executive Officer: Edward Stewart Geary
- Chief Medical & Chief Clinical Officer-Neurology: Lynn D. Kramer
Shareholders
- Wellington Management Co. LLP (8.6%)
- Nomura Asset Management Co., Ltd. (5.7%)
- Nippon Life Insurance Co. (4.1%)
- Asset Management One Co., Ltd. (3.4%)
- Eisai Co., Ltd. (3.3%)
- Daiwa Asset Management Co. Ltd. (2.7%)
- Nikko Asset Management Co., Ltd. (2.7%)
- The Vanguard Group, Inc. (2.5%)
- Sumitomo Mitsui Trust Asset Management Co., Ltd. (2.4%)
- Resona Holdings, Inc. (2.2%)
Contact Details
- Website:http://www.eisai.co.jp
- Address: 4-6-10 Koishikawa, Bunkyo-Ku, Tokyo, 112-8088, Japan
- Phone: +81.3.3817.3700
Related Companies
- Eisai Europe Ltd.
- Eisai LLC
- Eisai Machinery China Co. Ltd.
- Eisai Laboratorios S de RL de CV
- Eisai GesmbH
- Eisai Farmaceutica, Unipessoal Lda.
- Eisai Clinical Research Singapore Pte Ltd.
- Eisai Ltd. (Canada)
- Eisai SA/NV
- Eisai (Malaysia) Sdn. Bhd.
- Eisai (Thailand) Marketing Co. Ltd.
- Eisai AB
- Eisai Pharma AG
- Eisai (Singapore) Pte Ltd.
- Eisai Co. Ltd. /Misato Factory/
- Eisai Board Incentive Plan
- Eisai Corporate Pension Fund
- Eisai Pension Fund
- Eisai China, Inc.
- H3 Biomedicine, Inc.
- Eisai R&D Management Co., Ltd.
- Herusu Co., Ltd.
- Gakuen Shoji Co., Ltd.
- PT Eisai Indonesia
- Eisai Taiwan, Inc.
- Eisai (Hong Kong) Co. Ltd.
- Eisai Australia Pty Ltd.
- Eisai Pharmaceuticals India Pvt Ltd.
- Eisai GmbH
- Eisai SRL
Competitors
- JW Holdings Corporation
- Celltrion Pharm Inc.
- Ipsen SA
- Boryung Pharmaceutical Co., Ltd.
- Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A
- Denali Therapeutics Inc.
- Exelixis, Inc.
- Arcutis Biotherapeutics Inc
- Blueprint Medicines Corp.
- Oncternal Therapeutics, Inc.
- Genkyotex SA
- Seattle Genetics, Inc.
- Vivoryon Therapeutics AG
- ACADIA Pharmaceuticals Inc.
- Spring Bank Pharmaceuticals, Inc.
- Minerva Neurosciences Inc
- Aptinyx Inc
- Xenon Pharmaceuticals Inc.
- Aprea Therapeutics, Inc.
- Genfit SA
- Aduro BioTech, Inc.
- Aeolus Pharmaceuticals, Inc.
- Mirati Therapeutics Inc.
- Cortexyme, Inc.
- InnoCare Pharma Limited
- AC Immune SA
- AVEO Pharmaceuticals, Inc.
- Heron Therapeutics Inc
- Phathom Pharmaceuticals, Inc.
- Marinus Pharmaceuticals Inc
Copyright © 2020 FactSet Research Systems Inc. All rights reserved.
Last Updated on 10 Jul, 2020